JP2014513097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513097A5 JP2014513097A5 JP2014508463A JP2014508463A JP2014513097A5 JP 2014513097 A5 JP2014513097 A5 JP 2014513097A5 JP 2014508463 A JP2014508463 A JP 2014508463A JP 2014508463 A JP2014508463 A JP 2014508463A JP 2014513097 A5 JP2014513097 A5 JP 2014513097A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- amide
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 17
- -1 SAR543 Chemical compound 0.000 claims 12
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 11
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 10
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 10
- 229960001302 ridaforolimus Drugs 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 229960000235 temsirolimus Drugs 0.000 claims 10
- QLHHRYZMBGPBJG-UHFFFAOYSA-N 1-[4-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-pyrazolo[3,4-d]pyrimidinyl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C1=NC(N2CC3CCC(O3)C2)=C(C=NN2C3CCC4(CC3)OCCO4)C2=N1 QLHHRYZMBGPBJG-UHFFFAOYSA-N 0.000 claims 8
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims 8
- 229940124302 mTOR inhibitor Drugs 0.000 claims 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 7
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 5
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 5
- CGTADGCBEXYWNE-GTTQIJKGSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-GTTQIJKGSA-N 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 4
- 208000008069 Geographic Atrophy Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 208000002927 Hamartoma Diseases 0.000 claims 4
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 208000021642 Muscular disease Diseases 0.000 claims 4
- 201000009623 Myopathy Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000009905 Neurofibromatoses Diseases 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 4
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 4
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000003176 fibrotic effect Effects 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 230000009826 neoplastic cell growth Effects 0.000 claims 4
- 201000004931 neurofibromatosis Diseases 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 229950009216 sapanisertib Drugs 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 4
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 3
- 201000008632 juvenile polyposis syndrome Diseases 0.000 claims 3
- 208000015768 polyposis Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 241000282461 Canis lupus Species 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 210000004100 adrenal gland Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000002758 colorectal adenoma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 claims 1
- 238000006029 Jeger synthesis reaction Methods 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478572P | 2011-04-25 | 2011-04-25 | |
| US61/478,572 | 2011-04-25 | ||
| PCT/US2012/034647 WO2012148846A1 (en) | 2011-04-25 | 2012-04-23 | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016224893A Division JP2017061527A (ja) | 2011-04-25 | 2016-11-18 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513097A JP2014513097A (ja) | 2014-05-29 |
| JP2014513097A5 true JP2014513097A5 (enExample) | 2015-06-18 |
| JP6086902B2 JP6086902B2 (ja) | 2017-03-01 |
Family
ID=46018130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508463A Expired - Fee Related JP6086902B2 (ja) | 2011-04-25 | 2012-04-23 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ |
| JP2016224893A Pending JP2017061527A (ja) | 2011-04-25 | 2016-11-18 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016224893A Pending JP2017061527A (ja) | 2011-04-25 | 2016-11-18 | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20140066474A1 (enExample) |
| EP (1) | EP2701703A1 (enExample) |
| JP (2) | JP6086902B2 (enExample) |
| KR (1) | KR101925656B1 (enExample) |
| CN (1) | CN103491955B (enExample) |
| AR (1) | AR086481A1 (enExample) |
| AU (2) | AU2012250010A1 (enExample) |
| BR (1) | BR112013027486A2 (enExample) |
| CA (1) | CA2833962A1 (enExample) |
| CL (1) | CL2013003078A1 (enExample) |
| CO (1) | CO6801759A2 (enExample) |
| EA (1) | EA025948B1 (enExample) |
| EC (1) | ECSP13012994A (enExample) |
| GT (1) | GT201300263A (enExample) |
| IL (1) | IL229008A (enExample) |
| MA (1) | MA35038B1 (enExample) |
| MX (1) | MX2013012385A (enExample) |
| NZ (1) | NZ615593A (enExample) |
| PE (1) | PE20140601A1 (enExample) |
| PH (1) | PH12013502077A1 (enExample) |
| SG (1) | SG193919A1 (enExample) |
| TN (1) | TN2013000392A1 (enExample) |
| TW (1) | TWI602567B (enExample) |
| UA (1) | UA110961C2 (enExample) |
| WO (1) | WO2012148846A1 (enExample) |
| ZA (1) | ZA201306973B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140088869A (ko) * | 2011-11-02 | 2014-07-11 | 노파르티스 아게 | Vegf-의존성 질환의 치료에 사용하기 위한 2-카르복스아미드 시클로아미노 우레아 유도체 |
| HK1219421A1 (zh) * | 2013-03-15 | 2017-04-07 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| JP2016537345A (ja) * | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| EP3104890A1 (en) * | 2014-02-11 | 2016-12-21 | Novartis AG | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
| WO2015148626A1 (en) * | 2014-03-26 | 2015-10-01 | Millennium Pharmaceuticals, Inc. | Treatment of fibrotic disorders |
| CA2962714C (en) * | 2014-10-03 | 2023-09-19 | Novartis Ag | Pharmaceutical compositions comprising alpelisib |
| US20160339030A1 (en) * | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
| JP6691337B2 (ja) * | 2016-02-29 | 2020-04-28 | 学校法人北里研究所 | 膀胱癌患者の予後を予測するための方法 |
| GB202010627D0 (en) * | 2020-07-10 | 2020-08-26 | Qbd (Qs-Ip) Ltd | Blocking method |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| JP4105761B2 (ja) | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | ラパミシン（マクロライド）の半合成類似体免疫調節剤 |
| SG64372A1 (en) | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
| AU712193B2 (en) | 1995-06-09 | 1999-10-28 | Novartis Ag | Rapamycin derivatives |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| EP2662082A1 (en) * | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2349275B1 (en) * | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
-
2012
- 2012-04-23 PE PE2013002391A patent/PE20140601A1/es not_active Application Discontinuation
- 2012-04-23 MA MA36325A patent/MA35038B1/fr unknown
- 2012-04-23 CA CA2833962A patent/CA2833962A1/en not_active Abandoned
- 2012-04-23 MX MX2013012385A patent/MX2013012385A/es unknown
- 2012-04-23 AU AU2012250010A patent/AU2012250010A1/en not_active Abandoned
- 2012-04-23 CN CN201280020528.4A patent/CN103491955B/zh not_active Expired - Fee Related
- 2012-04-23 EP EP12717568.5A patent/EP2701703A1/en not_active Withdrawn
- 2012-04-23 EA EA201391565A patent/EA025948B1/ru not_active IP Right Cessation
- 2012-04-23 WO PCT/US2012/034647 patent/WO2012148846A1/en not_active Ceased
- 2012-04-23 US US14/113,316 patent/US20140066474A1/en not_active Abandoned
- 2012-04-23 AR ARP120101389A patent/AR086481A1/es unknown
- 2012-04-23 NZ NZ615593A patent/NZ615593A/en not_active IP Right Cessation
- 2012-04-23 BR BR112013027486A patent/BR112013027486A2/pt not_active Application Discontinuation
- 2012-04-23 SG SG2013070461A patent/SG193919A1/en unknown
- 2012-04-23 KR KR1020137027718A patent/KR101925656B1/ko not_active Expired - Fee Related
- 2012-04-23 UA UAA201311138A patent/UA110961C2/uk unknown
- 2012-04-23 PH PH1/2013/502077A patent/PH12013502077A1/en unknown
- 2012-04-23 JP JP2014508463A patent/JP6086902B2/ja not_active Expired - Fee Related
- 2012-04-24 TW TW101114591A patent/TWI602567B/zh not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06973A patent/ZA201306973B/en unknown
- 2013-09-27 TN TNP2013000392A patent/TN2013000392A1/fr unknown
- 2013-10-21 IL IL229008A patent/IL229008A/en active IP Right Grant
- 2013-10-24 CL CL2013003078A patent/CL2013003078A1/es unknown
- 2013-10-24 CO CO13252726A patent/CO6801759A2/es not_active Application Discontinuation
- 2013-10-25 EC ECSP13012994 patent/ECSP13012994A/es unknown
- 2013-10-25 GT GT201300263A patent/GT201300263A/es unknown
-
2016
- 2016-04-14 AU AU2016202372A patent/AU2016202372B2/en not_active Ceased
- 2016-10-27 US US15/335,957 patent/US20170095463A1/en not_active Abandoned
- 2016-11-18 JP JP2016224893A patent/JP2017061527A/ja active Pending
-
2017
- 2017-09-26 US US15/715,865 patent/US20180085362A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513097A5 (enExample) | ||
| JP2012506898A5 (enExample) | ||
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| Meadows et al. | Anti-VEGF therapies in the clinic | |
| Bucheit et al. | Emerging insights into resistance to BRAF inhibitors in melanoma | |
| RU2011121508A (ru) | Комбинация ингибитора фосфатидилинозитол-3-киназы (р13к) и ингибитора mtor | |
| JP2009514870A5 (enExample) | ||
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2015534577A5 (enExample) | ||
| JP2009539870A5 (enExample) | ||
| AU2016202372B2 (en) | Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor | |
| JP2015500884A5 (enExample) | ||
| Mirone et al. | Signaling mechanisms of resistance to EGFR-and anti-angiogenic inhibitors cancer | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| Devarakonda et al. | Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma | |
| CN114302746A (zh) | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 | |
| JP2018528949A5 (enExample) | ||
| JP2017536397A (ja) | 線維症の治療方法 | |
| RU2016135413A (ru) | Фармацевтические комбинации, включающие ингибитор pi3k, для лечения рака | |
| WO2022056592A1 (en) | Treatment and/or prevention of cancers | |
| Su et al. | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma | |
| Chugh | Experimental therapies and clinical trials in bone sarcoma | |
| JP2018535997A5 (enExample) | ||
| Kuczynski | Mechanisms of reversible sorafenib resistance in hepatocellular carcinoma | |
| Grothey | Chemotherapy of Advanced Colorectal Cancer |